Acute Coronary Syndrome (ACS), Dyspnea, Myocardial Infarction (MI), Ticagrelor, Caffeine. Acute Coronary Syndrome, Dyspnea, Ticagrelor, Adverse effect, Myocardial Infarction
Conditions
Interventions
Intervention 1: Intervention group 1: Participants receive oral caffeine (100 mg daily) in addition to the standard antiplatelet therapy Ticagrelor. Intervention 2: Intervention group 2 : Participants
Sponsors
Iran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: Willingness to participate in the study (signed informed consent). Age between 18 and 60 years. First-time prescription of ticagrelor as determined by the treating physician. Patients who have undergone coronary angioplasty (PCI).
Exclusion criteria
Exclusion criteria: History of stroke (CVA). Allergy or hypersensitivity to ticagrelor or caffeine. Conditions in which caffeine use is contraindicated. Patients using drugs that interact with ticagrelor. Severe heart failure (ejection fraction <40%). Chronic pulmonary diseases, such as asthma or COPD. Renal diseases, including chronic kidney disease (CKD) or acute kidney injury (AKI). Uncontrolled diabetes mellitus. History of pulmonary embolism. Patients requiring triple therapy (aspirin, antiplatelet, and anticoagulant). Pregnant or breastfeeding women.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Severity of dyspnea measured by modified borg scale. Timepoint: measurement of dyspnea at days 0, 3, 7, 14. Method of measurement: Modified Borg Scale Questionnaire. | — |
Secondary
| Measure | Time frame |
|---|---|
| The effect of caffeine on the rate of premature discontinuation of medication by patients. Timepoint: ????? ??? ???? ?? ??? ??? ?. ?. ? ? ??. Method of measurement: ???? ????. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactArian Raad
Iran University of Medical Sciences
Outcome results
None listed